{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T03:14:58Z","timestamp":1790565298671,"version":"4.1.0"},"reference-count":52,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>The Centers for Medicare &amp; Medicaid Services (CMS) established a class\u2010based National Coverage Determination (NCD) for monoclonal antibodies directed against amyloid for Alzheimer's disease (AD) with patient access through Coverage with Evidence Development (CED) based on three questions. This review, focused on donanemab, answers each of these CED questions with quality evidence. TRAILBLAZER\u2010ALZ registration trials are presented with supporting literature and real\u2010world data to answer CED questions for donanemab. TRAILBLAZER\u2010ALZ registration trials demonstrated that donanemab significantly slowed cognitive and functional decline in amyloid\u2010positive early symptomatic AD participants, and lowered their risk of disease progression while key safety risks occurred primarily within the first 6 months and then declined. Donanemab meaningfully improved health outcomes with a manageable safety profile in an early symptomatic AD population, representative of Medicare populations across diverse practice settings. The donanemab data provide the necessary level of evidence for CMS to open a reconsideration of their NCD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Highlights<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>Donanemab meaningfully improved outcomes in trial participants with early symptomatic Alzheimer's disease.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Comorbidities in trial participants were consistent with the Medicare population.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Co\u2010medications in trial participants were consistent with the Medicare population.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Risks associated with treatment tended to occur in the first 6 months.<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Risks of amyloid\u2010related imaging abnormalities were managed with careful observation and magnetic resonance imaging monitoring.<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/alz.13700","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T07:00:17Z","timestamp":1707289217000},"page":"3127-3140","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["How donanemab data address the coverage with evidence development questions"],"prefix":"10.1002","volume":"20","author":[{"given":"Eric G.","family":"Klein","sequence":"first","affiliation":[{"name":"Global Medical Affairs, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Schroeder","sequence":"additional","affiliation":[{"name":"Research and Development, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alette M.","family":"Wessels","sequence":"additional","affiliation":[{"name":"Research and Development, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Phipps","sequence":"additional","affiliation":[{"name":"Lilly Value and Access, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Japha","sequence":"additional","affiliation":[{"name":"Corporate Affairs, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Traci","family":"Schilling","sequence":"additional","affiliation":[{"name":"Global Medical Affairs, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Zimmer","sequence":"additional","affiliation":[{"name":"Research and Development, Eli Lilly and Company Lilly Corporate Center  Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12328"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(20)32205\u20104"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.12.1615"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182661f74"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41593\u2010020\u20100687\u20106"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2012.10.029"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2021.56"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12112"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000200127"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/bf02815140"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp062"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.1064"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2015.82"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2018.10"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3233\/jad\u2010220303"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002093-199700112-00005"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12876"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40120\u2010023\u201000443\u20102"},{"key":"e_1_2_10_23_1","unstructured":"Centers for Medicare and & Medicaid Services (CMS).Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease.2022. Accessed August 11 2023.https:\/\/www.cms.gov\/newsroom\/fact\u2010sheets\/medicare\u2010coverage\u2010policy\u2010monoclonal\u2010antibodies\u2010directed\u2010against\u2010amyloid\u2010treatment\u2010alzheimers\u2010disease"},{"key":"e_1_2_10_24_1","unstructured":"Centers for Medicare and & Medicaid Services (CMS).Monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease.2022. Accessed August 11 2023.https:\/\/www.cms.gov\/medicare\u2010coverage\u2010database\/view\/ncacal\u2010decision\u2010memo.aspx?proposed=N&ncaid=305"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12959"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12181"},{"key":"e_1_2_10_27_1","unstructured":"Alzheimer's Association.Experts reframe \u201cclinical meaningfulness\u201d in Alzheimer's. Accessed April 07 2023.https:\/\/www.alz.org\/news\/2023\/clinical\u2010meaningfulness\u2010definition#:~:text=A%202021%20article%20from%20the %2C%20functions%2C%20or%20survives.%E2%80%9D"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1474\u20104422(06)70677\u20109"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2016.115"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000007831"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12312"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2019.06.005"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.102"},{"key":"e_1_2_10_34_1","unstructured":"ApostolovaLG.The clinical relevance of the TRAILBLAZER\u2010ALZ 2 findings.Alzheimer's Association International Conference.2023.https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/83299"},{"key":"e_1_2_10_35_1","doi-asserted-by":"crossref","unstructured":"SchroederK AfonsoAS WangH GraceS PhippsA SimsJR.Characterize demographics comorbidities and co\u2010medications in newly diagnosed United States (US) Alzheimer's disease patients using Medicare claims.Alzheimer's Association International Conference.2023.https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/73825","DOI":"10.1002\/alz.073825"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glab373"},{"key":"e_1_2_10_37_1","doi-asserted-by":"crossref","unstructured":"SolomonP ZimmerJA EvansCD et\u00a0al.TRAILBLAZER\u2010ALZ 2: a phase 3 study to assess safety and efficacy of donanemab in early symptomatic Alzheimer's disease.International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders.2022.https:\/\/cslide.ctimeetingtech.com\/adpd22\/attendee\/person\/1087","DOI":"10.1212\/WNL.98.18_supplement.1688"},{"key":"e_1_2_10_38_1","unstructured":"PeschinS FarberDJ TrinhJD.Fa\u00e7ade of evidence: how Medicare's coverage with evidence development rations care and exacerbates inequity. Accessed August 14 2023.https:\/\/www.agingresearch.org\/wp\u2010content\/uploads\/2023\/02\/Facade\u2010of\u2010Evidence\u2010CED\u20102\u201013\u20102023.pdf"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2018.09.009"},{"key":"e_1_2_10_40_1","unstructured":"U.S. Census.Percentage population aged 65 and over: 2013\u20102017. Accessed April 20 2023.https:\/\/www.census.gov\/content\/dam\/Census\/library\/visualizations\/time\u2010series\/demo\/older\u2010population\/Figure%201%20Population%20Aged%2065%20and%20Over.pdf"},{"key":"e_1_2_10_41_1","unstructured":"SimsJR.Donanemab in early symptomatic Alzheimer's disease: clinical efficacy results from TRAILBLAZER\u2010ALZ 2.Alzheimer's Association International Conference.2023.https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/83291"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.2214\/ajr.22.28461"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp\u20102014\u2010309493"},{"key":"e_1_2_10_44_1","unstructured":"SallowayS.Donanemab in early symptomatic Alzheimer's disease: safety results from TRAILBLAZER\u2010ALZ 2.Alzheimer's Association International Conference.2023.https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/83294"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.07.005"},{"key":"e_1_2_10_46_1","unstructured":"American Academy of Neurology.Formal reconsideration request: monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease [CAG\u201000460N].2023. Accessed August 15 2023.https:\/\/www.aan.com\/siteassets\/home\u2010page\/policy\u2010and\u2010guidelines\/advocacy\/comment\u2010letters\/23\u2010aan\u2010amended\u2010reconsideration\u2010request.pdf"},{"key":"e_1_2_10_47_1","unstructured":"KimballS.Alzheimer's patients may wait years to get treated with new drugs putting them at risk of more severe disease.2023. Accessed August 15 2023.https:\/\/www.cnbc.com\/2023\/04\/30\/alzheimers\u2010treatment\u2010patients\u2010may\u2010wait\u2010years\u2010for\u2010new\u2010drugs.html"},{"key":"e_1_2_10_48_1","unstructured":"Health Resources & Services Administration.Workforce projections. Accessed June 13 2023.https:\/\/data.hrsa.gov\/topics\/health\u2010workforce\/workforce\u2010projections"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"key":"e_1_2_10_50_1","unstructured":"FDA.Lequmbi prescribing information.2023. Accessed October 06 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/761269s000lbl.pdf"},{"key":"e_1_2_10_51_1","unstructured":"FDA.Aduhelm prescribing information.2022. Accessed October 06 2023.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761178s005lbl.pdf"},{"key":"e_1_2_10_52_1","unstructured":"SolomonP.TRAILBLAZER\u2010ALZ 2: clinical background and study design.Alzheimer's Association International Conference.2023.https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/83292"},{"key":"e_1_2_10_53_1","doi-asserted-by":"crossref","unstructured":"PainA FergusonMB WangH.TRAILBLAZER\u2010ALZ 4: directly comparing donanemab to aducanumab on amyloid lowering in early symptomatic Alzheimer's disease\u2014Results from 12\u2010months.Alzheimer's Association International Conference.2023.https:\/\/alz.confex.com\/alz\/2023\/meetingapp.cgi\/Paper\/82529","DOI":"10.1002\/alz.082529"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alz.13700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T14:52:52Z","timestamp":1759935172000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/alz.13700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":52,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1002\/alz.13700"],"URL":"https:\/\/doi.org\/10.1002\/alz.13700","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]},"assertion":[{"value":"2023-10-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-12-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}